Healthcare Policy Changes Interpreted in Real-Time

The Challenge

The Challenge

A European-based pharmaceutical company with several products in the US market was under pressure to interpret and respond to rapidly changing US healthcare policies which could potentially impact access for their portfolio of oncology products.

When an executive order addressing the increasing prices of pharmaceutical drugs was signed, the company needed real-time guidance in order to formulate a strategy that would allow for continued US market access for their products.

The IP Solution

The IP Solution

To begin, IP’s team of policy experts in Washington DC reviewed the executive order and provided a clear, concise summary.

Our team then collected and reviewed feedback from leaders in pharmaceutical manufacturing, oncology societies, financial markets, as well as pharmacists and physicians, to gain insight into the perception of the executive order by key stakeholders across the oncology ecosystem.

Through analysis of this extensive input, our team identified common themes and advised on likely scenarios for future implementation of the executive order.

The Result

The Results

Working on a extremely tight deadline, IP successfully reviewed the healthcare policy and provided meaningful insights which impacted the company’s overall market access strategy.

Related Case Studies

A Comprehensive Launch Strategy Leads to Broad Access

A biopharmaceutical company was in the midst of bringing its first product to market with breakthrough therapy designation. The PDUFA date was fast approaching, and their small team needed guidance to steer them through the complicated access and reimbursement landscape.

Understanding the European Market

A mid-sized pharmaceutical company was looking to enter the European market through a compassionate use/early access pathway but lacked an understanding of the requirements specific to each country that would lead to broad access and reimbursement for their product across Europe.

Insight Into a New Therapeutic Landscape

A precision therapies-focused biopharmaceutical company was bringing their second product to market. In order to support product access at the provider level and drive market share and utilization, it was critical they understood the oncology clinical pathway landscape within two distinct therapeutic classes.